James S Kahn

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling
    Romulus Breban
    Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    BMC Public Health 9:S11. 2009
  2. ncbi request reprint Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial
    J Kahn
    Positive Health Program University of California San Francisco, San Francisco General Hospital, 94110, USA
    JAMA 282:2305-12. 1999
  3. doi request reprint Mentoring the next generation of HIV prevention researchers: a model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS research
    James Kahn
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 47:S5-9. 2008
  4. pmc Mentoring early-career scientists for HIV research careers
    James S Kahn
    Department of Medicine, University of California, San Francisco, CA 94110, USA
    Am J Public Health 99:S37-42. 2009
  5. doi request reprint What it takes: characteristics of the ideal personal health record
    James S Kahn
    San Francisco General Hospital, USA
    Health Aff (Millwood) 28:369-76. 2009
  6. pmc Personal health records in a public hospital: experience at the HIV/AIDS clinic at San Francisco General Hospital
    James S Kahn
    San Francisco General AIDS Program, Department of Medicine, University of California San Francisco, San Francisco, California 94110, USA
    J Am Med Inform Assoc 17:224-8. 2010
  7. ncbi request reprint Preventing hepatitis A and hepatitis B virus infections among men who have sex with men
    James Kahn
    Department of Medicine, Positive Health Program, University of California, San Francisco, and San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Infect Dis 35:1382-7. 2002
  8. ncbi request reprint Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study
    J O Kahn
    Positive Health Program, Dept of Medicine, University of California San Francisco, at San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 183:707-14. 2001
  9. ncbi request reprint Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial
    J O Kahn
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    JAMA 284:2193-202. 2000
  10. pmc The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation
    Elvin H Geng
    Division of HIV AIDS, San Francisco General Hospital, and Department of Medicine, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Clin Infect Dis 53:1008-14. 2011

Detail Information

Publications33

  1. pmc Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling
    Romulus Breban
    Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    BMC Public Health 9:S11. 2009
    ..Current measures of the clinical efficacy of antiretroviral therapy (ART) in the treatment of HIV include the change in HIV RNA in the plasma and the gain in CD4 cells...
  2. ncbi request reprint Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial
    J Kahn
    Positive Health Program University of California San Francisco, San Francisco General Hospital, 94110, USA
    JAMA 282:2305-12. 1999
    ..Adefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration...
  3. doi request reprint Mentoring the next generation of HIV prevention researchers: a model mentoring program at the University of California San Francisco and Gladstone Institute of Immunology and Virology Center for AIDS research
    James Kahn
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 47:S5-9. 2008
    ..We piloted a multidiscipline mentoring program targeting postdoctoral scholars and early career faculty concentrating on HIV/AIDS research...
  4. pmc Mentoring early-career scientists for HIV research careers
    James S Kahn
    Department of Medicine, University of California, San Francisco, CA 94110, USA
    Am J Public Health 99:S37-42. 2009
    ..Effective mentoring by focused mentors will likely contribute to the skills and networks of investigators necessary for the next generation of HIV investigators...
  5. doi request reprint What it takes: characteristics of the ideal personal health record
    James S Kahn
    San Francisco General Hospital, USA
    Health Aff (Millwood) 28:369-76. 2009
    ..However, in the future, when these concerns are addressed, and health data are portable and understandable (in both content and format), PHRs will likely prove to be invaluable...
  6. pmc Personal health records in a public hospital: experience at the HIV/AIDS clinic at San Francisco General Hospital
    James S Kahn
    San Francisco General AIDS Program, Department of Medicine, University of California San Francisco, San Francisco, California 94110, USA
    J Am Med Inform Assoc 17:224-8. 2010
    ..Patients in a safety net setting will access and use an online PHR...
  7. ncbi request reprint Preventing hepatitis A and hepatitis B virus infections among men who have sex with men
    James Kahn
    Department of Medicine, Positive Health Program, University of California, San Francisco, and San Francisco General Hospital, San Francisco, CA 94110, USA
    Clin Infect Dis 35:1382-7. 2002
    ..It is important for health care providers to educate and vaccinate their at-risk male patients against hepatitis A and hepatitis B virus infections...
  8. ncbi request reprint Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study
    J O Kahn
    Positive Health Program, Dept of Medicine, University of California San Francisco, at San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 183:707-14. 2001
    ..PEP, after nonoccupational HIV exposure, is feasible for persons at risk for HIV infection...
  9. ncbi request reprint Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial
    J O Kahn
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    JAMA 284:2193-202. 2000
    ..Agents that enhance the immunologic mechanism for viral recognition might reduce disease progression...
  10. pmc The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation
    Elvin H Geng
    Division of HIV AIDS, San Francisco General Hospital, and Department of Medicine, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Clin Infect Dis 53:1008-14. 2011
    ..Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164...
  11. doi request reprint 'Mobile' health needs and opportunities in developing countries
    James G Kahn
    University of California, San Francisco, CA, USA
    Health Aff (Millwood) 29:252-8. 2010
    ..We examine various m-health applications and define the risks and benefits of each. We find positive examples but little solid evaluation of clinical or economic performance, which highlights the need for such evaluation...
  12. pmc Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program
    Mitchell D Feldman
    Department of Medicine, University of California, San Francisco, USA
    Clin Transl Sci 2:216-21. 2009
    ..MITs reported increased confidence in overall and specific mentoring skills after completion of the MDP. The MDP can serve as a model for other institutions to develop the next generation of clinical-translational research mentors...
  13. pmc Characterizing HIV transmission networks across the United States
    Jeannette L Aldous
    Division of Infectious Diseases, University of California, San Diego, 200 W Arbor Dr, MC 8208, San Diego, CA 92103, USA
    Clin Infect Dis 55:1135-43. 2012
    ..Clinically, human immunodeficiency virus type 1 (HIV-1) pol sequences are used to evaluate for drug resistance. These data can also be used to evaluate transmission networks and help describe factors associated with transmission risk...
  14. pmc A cross-sectional study of barriers to personal health record use among patients attending a safety-net clinic
    Joan F Hilton
    Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e31888. 2012
    ....
  15. pmc A mentor development program for clinical translational science faculty leads to sustained, improved confidence in mentoring skills
    Mitchell D Feldman
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Clin Transl Sci 5:362-7. 2012
    ..We also describe a number of new initiatives to support mentoring at UCSF that have evolved from the MDP. To our knowledge, this is the first evaluation of the long-term impact of a mentor training program for CT researchers...
  16. pmc A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV
    Michelle E Roland
    Positive Health Program, Department of Internal Medicine, San Francisco General Hospital, San Francisco, California, USA
    Clin Infect Dis 53:76-83. 2011
    ..Intensive risk reduction and adherence counseling appear to be effective but are resource intensive. Identifying simpler interventions that maximize the HIV prevention potential of PEP is critical...
  17. pmc Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide
    David P Wilson
    Semel Institute for Neuroscience and Human Behavior, and Department of Biomathematics, David Geffen School of Medicine, University of California, 1100 Glendon Avenue, Penthouse 2, Los Angeles, CA 90024, USA
    Proc Natl Acad Sci U S A 103:14228-33. 2006
    ..Decisions about allocating scarce drugs should consider treatment equity as well as epidemiological consequences. Notably, a Durban-only DAS would lead to new disparities in healthcare between urban and rural areas in KwaZulu-Natal...
  18. ncbi request reprint Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy
    Mark A Jacobson
    Positive Health Program, Department of Medicine, University of California, San Francisco, USA
    AIDS 17:917-9. 2003
  19. ncbi request reprint HIV RNA testing in the context of nonoccupational postexposure prophylaxis
    Michelle E Roland
    Positive Health Program at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, CA 94110, USA
    J Infect Dis 190:598-604. 2004
    ..The specificity and positive predictive value of human immunodeficiency virus (HIV) RNA assays have not been evaluated in the setting of postexposure prophylaxis (PEP)...
  20. ncbi request reprint Use of laboratory tests and clinical symptoms for identification of primary HIV infection
    Frederick M Hecht
    Positive Health Program HIV Section at San Francisco General Hospital, tUniversity of California at San Francisco, 94110, USA
    AIDS 16:1119-29. 2002
    ..To determine the sensitivity and specificity of symptoms, three HIV-1 RNA assays, a p24 antigen EIA and a third-generation enzyme immunoassay (EIA) antibody test for diagnosis of primary HIV infection (PHI)...
  21. ncbi request reprint Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion
    Ronnie L Gascon
    University of California at San Francisco, Department of Medicine, 94110, USA
    J Acquir Immune Defic Syndr 30:146-53. 2002
    ..002). We conclude that monocyte activation as defined by elevation of CD14/DR expression correlates to CD4 T-cell depletion in primary HIV infection, and is predictive of a poor CD4 T-cell response to HAART in a subset of patients...
  22. ncbi request reprint Development of WF10, a novel macrophage-regulating agent
    Michael S McGrath
    AIDS Immunobiology Research Laboratory, San Francisco General Hospital Medical Center, CA 94110, USA
    Curr Opin Investig Drugs 3:365-73. 2002
    ..WF10 is currently being studied in the US, Europe and Asia for treatment of late-stage HIV disease, as well as recurrent prostate cancer, late post-radiation cystitis, autoimmune disease and chronic active hepatitis C disease...
  23. ncbi request reprint Time trends in primary HIV-1 drug resistance among recently infected persons
    Robert M Grant
    Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141, USA
    JAMA 288:181-8. 2002
    ..Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy...
  24. ncbi request reprint Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion
    Don E Smith
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW 2010, Australia
    AIDS Res Hum Retroviruses 19:189-99. 2003
    ..Despite poorer prognostic markers at baseline ES subjects achieved responses similar to those of LS subjects after 1 year of treatment...
  25. ncbi request reprint Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART
    Beatriz Martinez-Mariño
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 1270, USA
    AIDS 18:1991-9. 2004
    ..To determine the effect of interleukin-2 (IL-2) therapy on immunologic and virologic responses in subjects with acute or recent HIV infection already receiving highly active antiretroviral therapy (HAART)...
  26. ncbi request reprint Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus
    Steven D Pinkerton
    Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI 53202, USA
    Arch Intern Med 164:46-54. 2004
    ....
  27. ncbi request reprint Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior
    Jeffrey N Martin
    Department of Epidemiology and Biostatistics, the Center for AIDS Prevention Studies, and San Francisco, California 94105, USA
    AIDS 18:787-92. 2004
    ..The effectiveness of postexposure prophylaxis (PEP) following occupational exposure to HIV has prompted advocacy for PEP following sexual or drug-use exposures...
  28. ncbi request reprint Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
    Steven G Deeks
    San Francisco General Hospital, 995 Potrero Ave, San Francisco, CA 94110, USA
    Blood 104:942-7. 2004
    ..These data indicate that immunologic activation set point is established early in HIV infection, and that this set point determines the rate at which CD4+ T cells are lost over time...
  29. ncbi request reprint Seroconversion following nonoccupational postexposure prophylaxis against HIV
    Michelle E Roland
    Positive Health Program at San Francisco General Hospital, California, USA
    Clin Infect Dis 41:1507-13. 2005
    ..We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP...
  30. ncbi request reprint Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States
    Steven D Pinkerton
    Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53202, USA
    AIDS 18:2065-73. 2004
    ..To evaluate the cost-effectiveness of HIV postexposure prophylaxis (PEP) following sexual or injection-related exposures in 96 metropolitan statistical areas in the United States (MSA)...
  31. ncbi request reprint Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
    J Infect Dis 190:251-6. 2004
    ....
  32. pmc Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems
    Mari M Kitahata
    Department of Medicine, University of Washington, Seattle, 98195, USA
    Int J Epidemiol 37:948-55. 2008
  33. ncbi request reprint Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 17:2581-91. 2003
    ..However, their impact on viral replication during acute HIV-1 infection is not known...

Research Grants4

  1. Observational Cohort of HIV-Infected Persons
    James Kahn; Fiscal Year: 2005
    ..Dr. Kahn's research program has the enthusiastic support of his deuartment. the leadership of the AIDS Research Institute at UCSF and other nationally recognized clinical researchers. ..
  2. Integrating HIV Resistance Data into the CNICS Cohort
    James Kahn; Fiscal Year: 2004
    ..In this application we focus on adding the new data elements of viral resistance to the CNICS research network..
  3. Mentoring HIV and Translational Scientists and Developing an EMR Based Research
    James Kahn; Fiscal Year: 2007
    ....